{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:25Z","timestamp":1790959345576,"version":"4.1.0"},"reference-count":32,"publisher":"Tech Science Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2017,4,14]]},"abstract":"<jats:p>Gastric cancer (GC) is one of the main causes of cancer death. The tumor microenvironment has a profound effect on inducing tumor growth, metastasis, and immunosuppression. Fibroblast activation protein-\u03b1 (FAP) is a protein that is usually expressed in fibroblasts, such as cancer-associated\n fibroblasts, which are major components of the tumor microenvironment. However, the role of FAP in GC progression and treatment is still unknown. In this study, we explored these problems based on GC patient samples and experimental models. We found that high FAP expression was an independent\n prognosticator of poor survival in GC patients. FAP<jats:sup>+<\/jats:sup> cancer-associated fibroblasts (CAFs) promoted the survival, proliferation, and migration of GC cell lines in vitro. Moreover, they also induced drug resistance of the GC cell lines and inhibited the antitumor functions of T cells\n in the GC tumor microenvironment. More importantly, we found that targeting FAP<jats:sup>+<\/jats:sup> CAFs substantially enhanced the antitumor effects of immune checkpoint blockades in GC xenograft models. This evidence highly suggested that FAP is a potential prognosticator of GC patients and a target\n for synergizing with other treatments, especially immune checkpoint blockades in GC.<\/jats:p>","DOI":"10.3727\/096504016x14768383625385","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T03:11:18Z","timestamp":1493089878000},"page":"629-640","source":"Crossref","is-referenced-by-count":80,"title":["Fibroblast Activation Protein-\u03b1-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade"],"prefix":"10.32604","volume":"25","author":[{"given":"Xuyang","family":"Wen","sequence":"first","affiliation":[{"name":"Oncology Department, The 82nd Hospital of PLA, Huai\u2019an City, Jiangsu Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"He","sequence":"additional","affiliation":[{"name":"IMR Residency Program of Florida Hospital, Orlando, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The 82nd Hospital of PLA, Huai\u2019an City, Jiangsu Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The 82nd hospital of PLA, Huai\u2019an City, Jiangsu Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The 82nd Hospital of PLA, Huai\u2019an City, Jiangsu Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuequn","family":"Ren","sequence":"additional","affiliation":[{"name":"Medical Institution, Nanjing University, Nanjing, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department, The 82nd Hospital of PLA, Huai\u2019an City, Jiangsu Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","reference":[{"key":"b1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"b2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","year":"2015","journal-title":"CA Cancer J Clin."},{"key":"b3","first-page":"467","article-title":"Epidemiology of stomach cancer","volume-title":"Cancer epidemiology: Modifiable factors","year":"2009"},{"key":"b4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","article-title":"Japanese gastric cancer treatment guidelines 2010 (ver. 3)","volume":"14","year":"2011","journal-title":"Gastric Cancer"},{"key":"b5","first-page":"589","article-title":"Stomach cancer: 10 Years experiences with surgical treatment and possibilities for improving the prognosis","volume":"59","year":"1993","journal-title":"Helv Chir Acta"},{"key":"b6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-Year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","year":"2010","journal-title":"Lancet Oncol."},{"key":"b7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","article-title":"Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer","volume":"8","year":"1997","journal-title":"Ann Oncol."},{"key":"b8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(94)92464-3","article-title":"The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"b9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/jcb.21159","article-title":"Tumor microenvironment: The role of the tumor stroma in cancer","volume":"101","year":"2007","journal-title":"J Cell Biochem."},{"key":"b10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.27664","article-title":"Autophagic tumor stroma: Mechanisms and roles in tumor growth and progression","volume":"132","year":"2013","journal-title":"Int J Cancer"},{"key":"b11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF02147594","article-title":"Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction","volume":"27","year":"1971","journal-title":"Experientia"},{"key":"b12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","article-title":"Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression","volume":"31","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"b13","doi-asserted-by":"crossref","first-page":"e59102","DOI":"10.1371\/journal.pone.0059102","article-title":"Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"b14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","article-title":"The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance","volume":"2","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"b15","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer","volume":"110","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"b16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2407-6-57","article-title":"Characterization of gastric adenocarcinoma cell lines established from CEA424\/SV40 T antigen-transgenic mice with or without a human CEA transgene","volume":"6","year":"2006","journal-title":"BMC Cancer"},{"key":"b17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF02634257","article-title":"A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin","volume":"31","year":"1995","journal-title":"In Vitro Cell Dev Biol Anim."},{"key":"b18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","year":"2013","journal-title":"ACS Med Chem Lett."},{"key":"b19","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s00268-012-1520-5","article-title":"Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer","volume":"36","year":"2012","journal-title":"World J Surg."},{"key":"b20","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/annonc\/mdg726","article-title":"Gastric cancer: Epidemiology, pathology and treatment","volume":"14","year":"2003","journal-title":"Ann Oncol."},{"key":"b21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour-host interface","volume":"411","year":"2001","journal-title":"Nature"},{"key":"b22","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","year":"2008","journal-title":"Oncogene"},{"key":"b23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","year":"2004","journal-title":"Nat Med."},{"key":"b24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer","volume":"165","year":"2016","journal-title":"Cell"},{"key":"b25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI26532","article-title":"Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake","volume":"116","year":"2006","journal-title":"J Clin Invest."},{"key":"b26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","article-title":"Fibroblast activation protein: A serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis","volume":"37","year":"2006","journal-title":"Hum Pathol."},{"key":"b27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1025493605850","article-title":"Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells","volume":"20","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"b28","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"b29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4161\/cbt.13.3.18696","article-title":"Fibroblast activation protein: A potential therapeutic target in cancer","volume":"13","year":"2012","journal-title":"Cancer Biol Ther."},{"key":"b30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","article-title":"Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma","volume":"37","year":"2008","journal-title":"Pancreas"},{"key":"b31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1309\/AJCP86PPBNGOHNNL","article-title":"Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection","volume":"131","year":"2009","journal-title":"Am J Clin Pathol."},{"key":"b32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","article-title":"Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy","volume":"11","year":"2012","journal-title":"Mol Cancer Ther."}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20240529\/20240529170213_72945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:34:31Z","timestamp":1733520871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v25n4\/56844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4,14]]}},"alternative-id":["0965-0407(20170414)25:4L.629;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504016x14768383625385","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,14]]}}}